Serotonergic 5-HT6 receptor antagonists: Heterocyclic chemistry and potential therapeutic significance

Current Topics in Medicinal Chemistry

Volumn 15, Issue 17, 2015, Pages 1643-1662

  Bali, Alka ^a   Singh, Shalu ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

5 HT6 antagonists; Alzheimer s disease; Antiobesity agents; Cognition enhancers; Indole derivatives; Memory; Schizophrenia

Indexed keywords

ANTIOBESITY AGENT; BENZENE; CERLAPIRDINE; CHOLINERGIC RECEPTOR STIMULATING AGENT; CLOZAPINE; DIMEBON; FUSED HETEROCYCLIC RINGS; GABAERGIC RECEPTOR AFFECTING AGENT; HETEROCYCLIC COMPOUND; IDALOPIRDINE; INDOLE DERIVATIVE; LIGAND; NEUROTRANSMITTER; OLANZAPINE; SEROTONIN 5 HT6 RECEPTOR ANTAGONIST; SEROTONIN 5 RECEPTOR; SEROTONIN ANTAGONIST; SULFONAMIDE; SULFONE DERIVATIVE; UNCLASSIFIED DRUG; ZIPRASIDONE; SEROTONIN 6 RECEPTOR; SEROTONIN RECEPTOR;

ALZHEIMER DISEASE; ANXIETY; ARTICLE; BIOAVAILABILITY; CHEMICAL INTERACTION; COGNITION; DRUG RECEPTOR BINDING; GABAERGIC SYSTEM; HIGH THROUGHPUT SCREENING; HUMAN; MEDICINAL CHEMISTRY; MOLECULAR MODEL; NONHUMAN; OBESITY; PHARMACOPHORE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); SCHIZOPHRENIA; STRUCTURE ACTIVITY RELATION; CENTRAL NERVOUS SYSTEM DISEASES; CHEMICAL STRUCTURE; CHEMISTRY; METABOLISM;

CENTRAL NERVOUS SYSTEM DISEASES; LIGANDS; MOLECULAR STRUCTURE; RECEPTORS, SEROTONIN; SEROTONIN ANTAGONISTS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84931828604     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026615666150427110420     Document Type: Article

References (187)

1. Nichols, D.E.; Nichols, C.D. Serotonin receptors. Chem. Rev., 2008, 108, 1614-1641.
2. Hoyer, D.; Clarke, D.E.; Fozard, J.R.; Hartig, P.R.; Martin, G.R.; Mylecharane, E.J.; Saxena, P.R.; Humphrey, P.P. International union of pharmacology classification of receptors for 5- hydroxytryptamine (serotonin). Pharmacol. Rev., 1994, 46, 157- 203.
3. Hoyer. D.; Martin, G.R. Classification and nomenclature of 5-HT receptors: a comment on current issues. Behav. Brain. Res., 1996, 73, 263-268.
4. Sebben, M.; Ansanay, H.; Bockaert, J.; Dumuis, A. 5-HT6 receptors positively coupled to adenylyl cyclase in striatal neurones in culture. Neuroreport., 1995, 5, 2553-2557.
5. Monsma, F.J., Jr; Shen, Y.; Ward, R.P.; Hamblin, M. W.; Sibley, D.R. Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol. Pharmacol., 1993, 43, 320-327.
6. Ruat, M.; Traiffort, E.; Arrang, J.M.; Tardivel-Lacombe, J.; Diaz, J.; Leurs, R.; Schwartz, J.C. A novel rat serotonin (5-HT6) receptor: Molecular cloning, localization and stimulation of cAMP accumulation. Biochem. Biophys. Res. Commun., 1993, 193, 268- 276.
7. Unsworth, C.D.; Molinoff, P.B. Characterization of a 5- hydroxytryptamine receptor in mouse neuroblastoma N18TG2 cells. J. Pharmacol. Exp. Ther., 1994, 269, 246-255.
8. Kohen, R.; Metcalf, M.A.; Khan, N.; Druck, T.; Huebner, K.; Lachowicz, J.E.; Meltzer, H. Y.; Sibley, D.R.; Roth, B.L.; Hamblin, M.W. Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor. J. Neurochem., 1996, 66, 47-56.
9. Kohen, R.; Fashingbauer, L.A.; Heidmann, D.E.A.; Guthrie, C.R.; Hamblin, M.W. 2001. Cloning of the mouse 5-HT6 serotonin receptor and mutagenesis studies of the third cytoplasmic loop. Mol. Brain. Res., 2001, 90, 110-117.
10. Borsini, F.; Bordi, F.; Riccioni, T. 5-HT6 pharmacology inconsistencies. Pharmacol. Biochem. Behav., 2011, 98, 169-172.
11. Marazziti, D.; Baroni, S.; Borsini, F.; Picchetti, M.; Vatteroni, E.; Falaschi, V.; Catena-Dell'Osso, M. Serotonin receptors of type 6 (5-HT6): from neuroscience to clinical pharmacology. Curr. Med. Chem., 2013, 20, 371-377.
12. East, S.Z.; Burnet, P.W.J.; Leslie, R.A.; Roberts, J.C.; Harrison, P.J. 5-HT6 receptor binding sites in schizophrenia and following antipsychotic drug administration: Autoradiographic studies with[125I]SB-258585. Synapse, 2002, 4, 191-199.
13. Hirst, W.D, Abrahamsen, B.; Blaney, F.E.; Calver, A.R.; Aloj, L.; Price, G.W.; Medhurst, AD. Differences in the central nervous system distribution and pharmacology of the mouse 5- hydroxytryptamine-6 receptor compared with rat and human receptors investigated by radioligand binding, site-directed mutagenesis and molecular modeling. Mol. Pharmacol., 2003, 64, 1295-1308.
14. Heal, D.J.; Smith, S.L.; Fisas, A.; Codony, X.; Buschmann, H. Selective 5-HT6 receptor ligands: progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders. Pharmacol. Ther., 2008, 117, 207-231.
15. Geldenhuys, W.J.; Van der Schyf, C.J. Serotonin 5-HT6 receptor antagonists for the treatment of Alzheimer's disease. Curr. Top. Med. Chem., 2008, 8, 1035-1048.
16. Wesolowska, A. Potential role of the 5-HT6 receptor in depression and anxiety: an overview of preclinical data. Pharmacol. Rep., 2010, 62, 564-577.
17. Holenz, J.; Pauwels, P.J.; Diaz, J.L.; Merce, R.; Codony, X.; Buschmann, H. Medicinal chemistry strategies to 5-HT6 receptor ligands as potential cognitive enhancers and antiobesity agents. Drug Discovery Today, 2006, 11, 283-299.
18. Upton, N.; Chuang, T.T.; Hunter, A.J.; Virley, D.J. 5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer's disease. Neurotherapeutics, 2008, 5, 458-469.
19. Johnson, CN.; Ahmed, M.; Miller, N.D. 5-HT6 receptor antagonists: prospects for the treatment of cognitive disorders including dementia. Curr. Opin. Drug Discovery Dev., 2008, 11, 642-654.
20. Wilson, C.; Terry, A.V. Enhancing cognition in neurological disorders: potential usefulness of 5-HT6 antagonists. Drugs Future, 2009, 34, 969-975.
21. Liu, K.G.; Robichaud, A.J. 5-HT6 antagonists as potential treatment for cognitive dysfunction. Drug Dev. Res., 2009, 70, 145-168.
22. Geldenhuys, W.J.; Van der Schyf, C.J. The serotonin 5-HT6 receptor: a viable drug target for treating cognitive deficits in Alzheimer's disease. Exp. Rev. Neurother., 2009, 9, 1073-1085.
23. Rosse, G.; Schaffhauser, H. 5-HT6 receptor antagonists as potential therapeutics for cognitive impairment. Curr. Top. Med. Chem., 2010, 10, 207-221.
24. Codony, X.; Vela, J. M.; Ramirez, M.J. 5-HT6 receptor and cognition. Curr. Opin. Pharmacol., 2011, 11, 94-100.
25. Meneses, A.; Perez-Garcia, G.; Ponce-Lopez, T.; Castillo, C. 5-HT6 receptor memory and amnesia: behavioral pharmacology learning and memory processes. Int. Rev. Neurobiol., 2011, 96, 27-47.
26. Ramirez, M. J. 5-HT6 receptors and Alzheimer's disease. Alzheimer's Res.Ther., 2013, 5, 15.
27. Scarpini, E.; Scheltens, P.; Feldman, H. Treatment of Alzheimer's disease: current status and new perspectives. Lancet. Neurol., 2003, 2, 539-547.
28. Standridge, J.B. Pharmacotherapeutic approaches to the treatment of Alzheimer's disease. Clin. Ther., 2004, 26, 615-630.
29. Bullock, R.; Touchon, J.; Bergman, H.;Gambina, G.; He, Y.; Rapatz, G.; Nagel, J.; Lane, R. Rivastigmine and donepezil treatment in moderate to moderately severe Alzheimer's disease over a 2-year period. Curr. Med. Res. Opin.;,2005, 21, 1317- 27.
30. Mangialasche, F.; Solomon, A.; Winblad, B.; Mecocci, P.; Kivipelto, M. Alzheimer's disease: clinical trials and drug development. Lancet. Neurol., 2010, 9, 702-716.
31. Palmer, A.M. Neuroprotective therapeutics for Alzheimer's disease: progress and prospects. Trends. Pharmacol. Sci., 2011, 32, 141-147.
32. Anand, P.; Singh, B. A review on cholinesterase inhibitors for Alzheimer's disease. Arch. Pharm. Res., 2013, 36, 375-99.
33. Van der Staay, J.; Hinz, V.C.; Schmidt, B.H. Effects of metrifonate, its transformation product dichlorvos, and other organophosphorus and reference cholinesterase inhibitors on Morris water escape behavior in young-adult rats. J. Pharmacol. Exp. Ther., 1996, 278, 697-708.
34. Braida, D.; Paladini, E.; Griffini, P.; Lamperti, M.; Maggi, A.; Sala, M. An inverted U-shaped curve for heptylphysostigmine on radial maze performance in rats: comparison with other cholinesterase inhibitors. Eur. J. Pharmacol., 1996, 302, 13-20.
35. Rogers, D.C.; Robinson, T.L.; Quilter, C.A.; Hunter, A.J.; Routledge, C.; Hagan, J.J. Cognitive enhancement effects of the selective 5-HT6 antagonist SB-271046. Br. J. Pharmacol., 1999, 127, 22P.
36. Rogers, D.C.; Hagan, J.J. 5-HT6 receptor antagonists enhance retention of a water maze task in the rat. Psychopharmacol. (Berl.)., 2001, 158, 114-119.
37. Perez-Garcia, G.; Meneses, A. Oral administration of the 5-HT6 receptor antagonists SB-357134 and SB-399885 improves memory formation in an autoshaping learning task. Pharmacol.Biochem. Behav., 2005, 81, 673-682.
38. Garcia-Alloza, M., Hirst, W.D.; Chen, C.P.; Lasheras, B.; Francis, P.T.; Ramirez, M.J.Differential involvement of 5-HT1B/1D and 5- HT6 receptors in cognitive and non-cognitive symptoms in Alzheimer's disease. Neuropsychopharmacol., 2004, 29, 410-416.
39. Hatcher, P.D.; Brown, V.J.; Tait, D.S.; Bate, S.; Overend, P.; Hagan, J.J.; Jones, D.N. 5-HT6 receptor antagonists improve performance in an attentional set shifting task in rats. Psychopharmacol (Berl.)., 2005, 181, 253-259.
40. Lindner, M.D.; Hodges, D.B Jr.; Hogan, J.B.; Orie, A.F.; Corsa, J.A.; Barten, D.M.; Polson, C.; Robertson, B.J.; Guss, V.L.; Gillman, K.W.; Starrett, J.E. Jr.; Gribkoff, V.K. An assessment of the effects of serotonin 6 (5-HT6) receptor antagonists in rodent models of learning. J. Pharmacol. Exp. Ther., 2003, 307, 682-691.
41. Grailhe, R.; Boschert, U.; Hen, R. The 5-HT5, 5-HT6 and 5-HT7 receptors. Pharmacochem. Libr., 1997, 27, 311-323.
42. Sleight, A.J.; Boess, F.G.; Bourson, A.; Sibley, D.R.; Monsma Jr, F.J. 5-HT6 and 5-HT7 receptors: molecular biology, functional correlates and possible therapeutic indications. Drug News Perspect., 1997, 10, 214-224.
43. Branchek, T.A.; Blackburn, T.P. 5-HT6 receptors as emerging targets for drug discovery. Ann. Rev. Pharmacol. Toxicol., 2000, 40, 319-334.
44. Russell, M.G.N.; Dias, R. Memories are made of this (perhaps): a review of serotonin 5-HT6 receptor ligands and their biological functions. Curr. Top. Med. Chem., 2002, 6, 643-54.
45. Slassi, A.; Isaac, M.; O'Brien, A. Recent progress in 5-HT6 receptor antagonists for the treatment of CNS diseases. Expert. Opin. Ther. Pat., 2002, 12, 513-527.
46. Wood, M.D.; Thomas, D.R.; Watson, J.M. Therapeutic potential of serotonin antagonists in depressive disorders. Exp. Opin. Invest. Drugs; 2002, 11, 457-467.
47. Glennon, R.A. Higher-end serotonin receptors: 5-HT5, 5-HT6, and 5-HT7. J. Med. Chem., 2003, 46, 2795-2812.
48. Woolley, M.L.; Marsden, C.A.; Fone, K.C.F. 5-HT6 receptors. Curr Drug Targets: CNS Neurol. Disord., 2004, 3, 59-79.
49. Davies, S.L.; Silvestre, J.S.; Guitart, X. Drug discovery targets: 5- HT6 receptor. Drugs Future., 2005, 30, 479-495.
50. Mitchell, E.S.; Neumaier, J.F. 5-HT6 receptors: a novel target for cognitive enhancement. Pharmacol.Ther., 2005, 108, 320-333.
51. Benhamu, B.; Martin-Fontecha, M.; Vazquez-Villa, H.; Pardo, L.; Lopez-Rodriguez, M.L. Serotonin 5-HT6 Receptor Antagonists for the Treatment of Cognitive Deficiency in Alzheimer's Disease. J. Med. Chem., 2014, 57, 7160-7181.
52. Riemer, C.; Borroni, E.; Levet-Trafit, B.; Martin, J. R.; Poli, S.; Porter, R. H.P.; Bos, M. Influence of the 5-HT6 receptor on acetylcholine release in the cortex: pharmacological characterization of 4-(2-bromo-6-pyrrolidin-1-ylpyridine-4- sulfonyl)phenylamine, a potent and selective 5-HT6 receptor antagonist. J. Med. Chem., 2003, 46, 1273- 1276.
53. Marcos, B.; Gil-Bea, F.J.; Hirst, W.D.; Garcia-Alloza, M.; Ramirez, M.J. Lack of localization of 5-HT6 receptors on cholinergic neurons: implication of multiple neurotransmitter systems in 5-HT6 receptor-mediated acetylcholine release. Eur. J. Neurosci., 2006, 24, 1299-1306.
54. Schechter, L. E.; Lin, Q.; Smith, D. L.; Zhang, G. M.; Shan, Q.; Platt, B.; Brandt, M. R.; Dawson, L. A.; Cole, D.; Bernotas, R.; Robichaud, A.; Rosenzweig-Lipson, S.; Beyer, C. E. Neuropharmacological profile of novel and selective 5-HT6 receptor agonists: WAY-181187 and WAY-208466. Europsychopharmacol., 2008, 33, 1323-1335.
55. Dawson, L. A.; Nguyen, H. Q.; Li, P. The 5-HT6 receptor antagonist SB-271046 selectively enhances excitatory neurotransmission in the rat frontal cortex and hippocampus. Neuropsychopharmacol., 2001, 25, 662-668.
56. Lacroix, L.P.; Dawson, L.A.; Hagan, J.J.; Heidberger, C.A. 5-HT6 receptor antagonist SB-271046 selectively enhances extracellular levels of monoamines in the rat media prefrontal cortex. Synapse, 2004, 51, 158-164.
57. West, P. J.; Marcy, V. R.; Marino, M. J.; Schaffhauser, H. Activation of the 5-HT6 receptor attenuates long-term potentiation and facilitates GABAergic neurotransmission in rat hippocampus. Neuroscience., 2009, 164, 692-701.
58. Vickers, S.P. and Dourish, C.T. Serotonin receptor ligands and the treatment of obesity. Curr. Opin. Investig. Drugs., 2004, 5, 377- 388.
59. Bentley, J.C.; Marsden, C.A.; Sleight, A.J., Fone, K.C.F. 5-HT6 antisense oligonucleotide i.c.v. affects rat performance in the water maze and feeding. J. Psychopharmacol., 1997, 11, A64.
60. Heal, D.J.; Smith, S.L.; Fisas, A.; Codony, X.; Buschmann, H. Selective 5-HT6 receptor ligands: Progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders. Pharmacol. Therap., 2008, 117, 207- 231.
61. Woolley, M.L.;Bentley, J.C.; Sleight, A.J.; Marsden, C.A.; Fone, K.C. A role for 5-HT6 receptors in retention of spatial learning in the Morris water maze. Neuropharmacol., 2001, 41, 210-219.
62. Bentley, J.C.;Bourson, A.; Boess, F.G.; Fone, K.C.; Marsden, C.A.; Petit, N.; Sleight, A.J. Investigation of stretching behaviour induced by the selective 5-HT6 receptor antagonist Ro 04-6790 in rats. Br. J. Pharmacol., 1999, 126, 1537-1542.
63. Svartengren, J.; Ohman, B.; Edling, N.; Svensson, M.; Fholenhag, K.; Axelsson-Lendin, P.; Klingstrom, G.; Larsson, C. The Serotonin 5-HT6 receptor antagonist BVT.5182 reduces body weight of high fat diet-induced mice. Int. J. Obesity, 2003, 27, 1- 094.
64. Frassetto, A.; Zhang, J.; Lao, J.Z.; White, A.; Metzger, J.M.; Fong, T.M.; Chen, R.Z. Reduced sensitivity to diet-induced obesity in mice carrying a mutant 5-HT6 receptor. Brain Res., 2008, 1236, 140-144.
65. Jossan, S.; Nilsson, B.N.; Svartengren, S.J. Formulations comprising a 5-HT agonist and 5-HT6 antagonist useful for the treatment of obesity. WO patent 2002008178 2002.
66. Galletly, C.A.; Clark, C.R.; MacFarlane, A.C. Treating cognitive dysfunction in patients with schizophrenia. J. Psychiatry. Neurosci., 2000, 25, 117-124.
67. Kuperberg, G.; Heckers, S. Schizophrenia and cognitive function. Curr. Opin. Neurobiol., 2000, 10, 205-210.
68. Friedman, J.I. Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists. Psychopharmacol., 2004, 174, 45-53.
69. Stip, E.; Chouinard, S.; Boulay, L.J. On the trail of a cognitiveenhancer for the treatment of schizophrenia. Prog. Neuropsychopharmacol. Biol. Psych., 2005, 29, 219-232.
70. Peuskens, J.; Demily, C.; Thibaut, F. Treatment of cognitive dysfunction in schizophrenia. Clin Ther., 2005, 27, S25-S37.
71. Bowie, C.R.; Harvey, P.D. Treatment of cognitive deficits in schizophrenia. Curr. Opin. Invest. Drugs, 2006, 7, 608-613.
72. Ferreri, F.; Agbokou, C.; Gauthier, S. Cognitive dysfunctions in schizophrenia: potential benefits of cholinesterase inhibitor adjunctive therapy. J. Psychiatry. Neurosci, 2006, 31, 369-376.
73. Bowie Christopher, R.; Jaga, K. Methods for treating cognitive deficits in schizophrenia. Expert. Rev. Neurother., 2007, 7, 281- 287.
74. De Oliveira, I.R.; Juruena, M.F. Treatment of psychosis: 30 years of progress. J. Clin. Pharm. Ther; 2006, 31, 523-534.
75. Jarskog, L.F.; Miyamoto, S.; Lieberman, J.A. Schizophrenia: new pathological insights and therapies. Ann. Rev. Med., 2007, 58, 49- 61.
76. Goldberg, T.E.; Greenberg, R.D.; Griffin, S.J.; Gold, J.M.; Kleinman, J.E.; Pickar, D.; Schulz, S.C.; Weinberger, D.R. The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. Br. J. Psychiatry, 1993, 162, 43-48.
77. Harvey, P.D.; Keefe, R.S. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am. J. Psychiatry, 2001, 158, 176-184.
78. Bilder, R.M.; Goldman, R.S.; Volavka, J.; Czobor, P.; Hoptman, M,; Sheitman, B.; Lindenmayer, J-P.; Citrome, L.; McEvoy, J.; Kunz, M.; Chakos, M.; Cooper, T.B.; Horowitz, T.L.; Lieberman, J.A. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am. J. Psychiatry, 2002, 159, 1018-1028.
79. Harvey, P.D.; Napolitano, J.A.; Mao, L.; Gharabawi, G. Comparative effects of risperidone and olanzapine on cognition in elderly patients with schizophrenia or schizoaffective disorder. Int. J. Geriatr. Psychiatry, 2003, 18, 820-829.
80. Keefe, R.S.E.; Seidman, L.J.; Christensen, B.K.; Hamer, R.M.; Sharma, T.; Sitskoorn, M.M.; Lewine, R.J.; Yurgelun-Todd, D.A.; Gur Ruben, C.; Tohen, M.; Tollefson, G.D.; Sanger, T.M.; Lieberman, J.A. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am. J. Psychiatry, 2004, 161, 985-995.
81. Harvey, P.D.; Siu, C.O.; Romano, S. Randomized, controlled, double-blind, multicenter comparison of the cognitive effects of ziprasidone versus olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Psychopharmacol, 2004, 172, 324-332.
82. Harvey, P.D.; Rabinowitz, J.; Eerdekens, M.; Davidson, M. Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial. Am. J. Psychiatry, 2005, 162, 1888-1895.
83. Roth, B. L.; Craigo, S. C.; Choudhary, M. S.; Uluer, A.; Monsma, F. J., Jr.; Shen, Y.; Meltzer, H. Y.; Sibley, D. R. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5- hydroxytryptamine-7 receptors. J. Pharmacol. Exp. Ther, 1994, 268, 1403-1410.
84. Boess, F. G.; Monsma, F. J., Jr.; Meyer, V.; Zwingelstein, C.; Sleight, A. J. Interaction of tryptamine and ergoline compounds with threonine 196 in the ligand binding site of the 5- hydroxytryptamine6 receptor. Mol. Pharmacol., 1997, 52, 515-523.
85. Fredericks, J.A.; Woodruff, J.H. Effects of clozapine and haloperidol on 5-HT6 receptor mRNA levels in the rat brain. Schizophr. Res., 1999, 38, 7-12.
86. Pouzet, B.; Didriksen, M.; Arnt. J. Effects of the 5-HT (6) receptor antagonist, SB-271046, in animal models for schizophrenia. Pharmacol. Biochem. Behav., 2002, 71, 635-643.
87. Kurogi, Y.; Güner, O. F. Pharmacophore Modeling and Three- Dimensional Database Searching for Drug Design Using Catalyst. Curr. Med. Chem., 2001, 8, 1035-1055.
88. Pullagurla, M.R.; Westkaemper R.B.; Glennon, R.A. Possible differences in modes of agonist and antagonist binding at human 5- HT6 receptors. Bioorg. Med. Chem. Lett., 2004, 14, 4569-4573.
89. Hirst, W.D.; Abrahamsen, B.; Blaney, F.E.; Calver, A.R.; Aloj, L.; Price, G.W.; Medhurst, A.D. Differences in the central nervous system distribution and pharmacology of the mouse 5- hydroxytryptamine-6 receptor compared with rat and human receptors investigated by radioligand binding, site-directed mutagenesis, and molecular modeling. Mol. Pharmacol., 2003, 64, 1295-1308.
90. Lopez-Rodriguez M.L.; Benhamu, B.; de la Fuente, T.; Sanz, A.; Pardo, L.; Campillo, M. A three-dimensional pharmacophore model for 5-hydroxytryptamine6 (5-HT6) receptor antagonists. J. Med. Chem., 2005, 48, 4216-4219.
91. Bromidge, S. M.; Brown, A. M.; Clarke, S. E.; Dodgson, K.; Gager, T.; Grassam, H. L.; Jeffrey, P. M.; Joiner, G. F.; King, F. D.; Middlemiss, D. N.; Moss, S. F.; Newman, H.; Riley, G.; Routledge, C.; Wyman, P. 5-Chloro-N-(4-methoxy-3-piperazin-1-ylphenyl)- 3-methyl-2-benzothiophenesulfonamide (SB-271046): a potent, selective, and orally bioavailable 5-HT6 receptor antagonist. J. Med. Chem., 1999, 42, 202-205.
92. Nordvall, G.; Petersson, C.; Sehgelmeble, F. Benzoxazepinylbenzenesulfonamide and process for their preparation, intermediates, pharmaceutical compositions and their use in the treatment of 5-HT6 mediated disorders such as Alzheimer's disease, cognitive disorders, cognitive impairment associated with schizophrenia, obesity and Parkinson's disease. PCT Int. Appl. WO2007004959 A1, 2007.
93. Nordvall, G.; Petersson, C.; Rakos, L.; Sohn, D. Novel 8-sulfonyl- 3-amino-substituted chroman or tetrahydronaphthalene derivatives modulating the 5-HT6 receptor and their preparation and pharmaceutical compositions. PCT Int. Appl. WO2006126938 A1, 2006.
94. Riemer, C.; Borroni, E.; Levet-Trafit, B.; Martin, J. R.; Poli, S.; Porter, R. H. P.; Bos, M. Influence of the 5-HT6 receptor on acetylcholine release in the cortex: pharmacological characterization of 4-(2-bromo-6-pyrrolidin-1-ylpyridine-4-sulfonyl)phenylamine, a potent and selective 5-HT6 receptor antagonist. J. Med. Chem., 2003, 46, 1273-1276.
95. Hirst, W. D.; Stean, T. O.; Rogers, D. C.; Sunter, D.; Pugh, P.; Moss, S. F.; Bromidge, S. M.; Riley, G.; Smith, D. R.; Bartlett, S.; Heidbreder, C. A.; Atkins, A. R.; Lacroix, L. P.; Dawson, L. A.; Foley, A.G.; Regan, C. M.; Upton, N. SB-399885 is a potent, selective 5-HT6 receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models. Eur. J. Pharmacol., 2006, 553, 109-119.
96. Van Loevezijn, A.; Venhorst, J.; Iwema Bakker, W. I.; de Korte, C.G.; de Looff, W.; Verhoog, S.; van Wees, J. W.; van Hoeve, M.; van deWoestijne, R. P.; van der Neut, M. A.; Borst, A. J.; van Dongen, M. J.; de Bruin, N. M.; Keizer, H. G.; Kruse, C. G. N′- (Arylsulfonyl)pyrazoline-1-carboxamidines as novel, neutral 5- hydroxytryptamine 6 receptor (5-HT6R) antagonists with unique structural features. J. Med. Chem., 2011, 54, 7030-7054.
97. Glennon, R. A.; Lee, M.; Rangisetty, J. B.; Dukat, M.; Roth, B. L.; Savage, J. E.; McBride, A.; Rauser, L.; Hufeisen, S.; Lee, D. K. H. 2-Substituted tryptamines: agents with selectivity for 5-HT6 serotonin receptors. J. Med. Chem., 2000, 43, 1011-1018.
98. Lee, M.; Rangisetty, J. B.; Dukat, M.; Slassi, A.; Maclean, N.; Lee,D. K. H.; Glennon, R. A. 5-HT6 serotonin receptor binding affinities ofN-1-benzenesulfonyl and related tryptamines. Med. Chem. Res., 2000, 10, 230-242.
99. Russell, M.G.N.; Baker, R.J.; Barden, L.; Beer, M.S.; Bristow, L.; Broughton, H.B.; Knowles, M.; McAllister, G.; Patel, S.; Castro, J.L. N-Arylsulfonylindole derivatives as serotonin 5-HT6 receptor ligands. J. Med. Chem., 2001, 44, 3881-3895.
100. Tsai, Y. Dukat, M.; Slassi, A.; MacLean, N.; Demchyshyn, L.; Savage, J.E.; Roth, B.L.; Hufesein, S.; Lee, M.; Glennon, R.A. N1- (Benzenesulfonyl)tryptamines as novel 5-HT6 antagonists. Bioorg. Med. Chem. Lett., 2000, 10, 2295-2299
101. Slassi, A.; Edwards, L.; O'Brien, A.; Xin, T.; Tehim, A. Preparation of 3-(2-pyrrolidinylmethyl)indoles as 5-HT6 antagonists. PCT Int. Appl. WO9947516 A1, 1999.
102. Slassi, A.; Edwards, L.; O'Brien, A.; Xin, T.; Tehim, A. Preparation of 1-(arylsulfonyl)-3-tetrahydropyridinyl indoles as 5-HT6 receptor inhibitors.U.S. Pat.Appl. US6133287A, 2000.
103. Cole, D.C.; Ellingboe, J.W.; Lennox, W.J.; Mazandarani,H.; Smith,D.L.; Stock, J.R.; Zhang, G.; Zhoub, P.; Schechterc, L.E. N1-arylsulfonyl-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole derivatives are potent and selective 5-HT6 receptor antagonists. Bioorg. Med. Chem. Lett., 2005, 15, 379-383.
104. Briggs, A.J.; Clark, R.D.; Harris, R.N., III; Repke, D.B.; Wren, D.L. Preparation of 4-piperazinylindoles with 5-HT6 receptor affinity. PCT Int. Appl. WO2002102774 A1, 2002.
105. Bromidge, S.M. Preparation of 4-piperazinoindoles for treating CNS disorders.PCT Int. Appl. WO2002041889 A2, 2002.
106. Caldirola, P.; Johansson, G.; Nilsson, B.M. 2-, 3-, 4-, or 5- Substituted-1-(benzenesulfonyl)indoles and their use in therapy. PCT Int. Appl. WO2002032863 A1, 2002.
107. Ahmed, M.; Briggs, M. A.; Bromidge, S. M.; Buck, T.; Campbell, L.; Deeks, N. J.; Garner, A.; Gordon, L.; Hamprecht, D. W.; Holland, V.; Johnson, C. N.; Medhurst, A. D.; Mitchell, D. J.; Moss, S. F.; Powles, J.; Seal, J. T.; Stean, T. O.; Stemp, G.; Thompson, M.; Trail, B.; Upton, N.; Winborn, K.; Witty, D. R. Bicyclic heteroarylpiperazines as selective brain penetrant 5-HT6 receptor antagonists. Bioorg. Med. Chem. Lett., 2005, 15, 4867-4871.
108. Nirogi, R.V.S.; Badange, R.; Kambhampati, R.; Chindhe, A.; Deshpande, A.D.; Tiriveedhi, V.; Kandikere, V.; Muddana, N.; Abraham, R.; Khagga, M. Design, synthesis and pharmacological evaluation of 4-(piperazin-1-ylmethyl)-N1-arylsulfonyl indole derivatives as 5-HT6 receptor ligands. Bioorg. Med. Chem. Lett., 2012, 22, 7431-7435.
109. Liu, K.G.; Lo, J.R.; Comery,T.A.; Zhang,G.M.; Zhang, J.Y.; Kowal, D.M.; Smith, D.L.; Di, L.; Kerns, E.H.; Schechter, L.E.; Robichaud, A.J. A regiospecific synthesis of a series of 1-sulfonyl azepinoindoles as potent 5-HT6 ligands. Bioorg. Med. Chem. Lett., 2008, 18, 3929-3931.
110. Henderson, A.J.; Guzzo, P.R.; Ghosh, A, Kaur,J.; Koo, J.M.; Nacro, K.; Panduga, S.; Pathak, R.; Shimpukade, B.; Tan, V.; Kai Xiang K.; Wierschke, J.D.; Isherwood, M.L. Epiminocyclohepta[ b]indole analogs as 5-HT6 antagonists. Bioog. Med. Chem. Lett., 2012, 22, 1494-1498
111. Kolanos, R.; Dukat, M.; Rothb, B.L.; Glennon, R.A. Interaction of N1-unsubstituted and N1-benzenesulfonyltryptamines at h5-HT6 receptors. Bioorg. Med. Chem. Lett., 2006, 16, 5832-5835.
112. Holenz, J.; Merce, R.; Diaz, J.L.; Guitart, X.; Codony, X.; Dordal, A.; Romero, G.;Torrens, A.; Mas, J.; Andaluz, B.; Hernandez, S.;Monroy, X.; Sanchez, E.; Hernandez, E.; Perez, R.; Cubi, R.; Sanfeliu, O.;Buschmann, H. Medicinal chemistry driven approaches toward noveland selective serotonin 5-HT6 receptor ligands. J. Med. Chem., 2005, 48, 1781-1795.
113. Cole, D.C.; Lennox, W.J.; Lombardi, S.; Ellingboe, J.W.; Bernotas, R.C.; Tawa, G.J.; Mazandarani, H.; Smith, D.L.;Zhang, G.; Coupet, J.; Schechter, L.E. Discovery of 5-Arylsulfonamido-3-(pyrrolidin- 2-ylmethyl)-1H-indole Derivatives as Potent, Selective 5-HT6 Receptor Agonists and Antagonists. J. Med. Chem., 2005, 48, 353- 356.
114. Schreiber, R.; Vivian, J.; Hedley, L.; Szczepanski, K.; Secchi, R.L.; Zuzow, M.; Laarhoven, S.V.; Moreau, J.L.; Martin, J.R.; Sik, A.; Blokland, A. Effects of the novel 5-HT6 receptor antagonist RO4368554 in rat models for cognition and sensorimotor gating. European Neuropsychopharmacol., 2007, 17, 277-288.
115. Filla, S.A.; Flaugh, M.E.; Gillig, J.R.; Heinz, L.J.; Krushinski, J.H., Jr.; Liu, B.X.; Pineiro-Nunez, M. M.; Schaus, J. M.; Ward, J. S. Preparation of benzenesulfonic acid indol-5-yl esters as antagonists of the 5-HT6 receptor. PCT Int. Appl. WO2002060871 A2, 2002.
116. Cole, D.C.; Kelly, M.G.; Bravo, B.A.; Palmer, Y. L. Preparation of 1-(indol-3-yl)alkylidenehydrazine carboximidamides as 5- hydroxytryptamine-6 ligands. U.S. Pat. Appl. US20030232843 A1, 2003.
117. Schechter, L.E.; Smith, D.L.; Zhang, G.M.; Li, P.; Lin, Q.; Lucki, I.; Rosenzweig-Lipson, S.; Robichaud, A.; Bernotas, R.; Beyer, C.E. WAY-466: In vitro and in vivo pharmacological characterization of a novel and selective 5-HT6 receptor agonist. Neuropsychopharmacol., 2004, 29 (Suppl. 1), S237
118. Ahmed, M.; Johnson, C.N.; Jones, M.C.; MacDonald, G.J.; Moss, S.F.; Thompson, M.; Wade, C.E.; Witty, D. Preparation of arylsulfonyl(diazacycloalkyl)quinolines for treatment of CNS disorders. WO Patent 2003080580, 2003.
119. Johnson, C.N.; Witty, D.R. Preparation of 8-(1-piperazinyl)- quinolines for treatment of CNS disorders. WO Patent 2005026125, 2005.
120. Johnson, C.N.; Moss, S.F.; Witty, D.R. Preparation of piperazinylquinolinederivatives useful for the treatment of CNS disorders.WO Patent 2005030724, 2005.
121. Bromidge, S.M.; Griffith, K.; Heightman, T.D.; Jennings, A.; King, F.D.; Moss, S.F.; Newman, H.; Riley, G.; Routledge, C.; Serafinowska, H.T.; Thomas, D.R. Novel (4-piperazin-1- ylquinolin-6-yl) arylsulfonamideswith high affinity and selectivity for the 5-HT6 receptor. Bioorg. Med. Chem Lett., 2001, 11, 2843- 2846.
122. Seong, C.M.; Park, W.K.; Park, C.M.; Kongb, J.Y.; Parka, N.S. Discovery of 3-aryl-3-methyl-1H-quinoline-2,4-diones as a new class of selective 5-HT6 receptor antagonists. Bioorg. Med. Chem. Lett., 2008, 18, 738-743.
123. Johansson, G.; Jenmalm-Jensen, A.; Beierlein, K. Preparation of pyridino-fused heterocycles useful for the treatment of obesity, type II diabetes and CNS disorders. PCT Int. Appl. WO2004000828 A1, 2003.
124. Xin, T.; Isaac, M.; Slassi, A. Bicyclic amine derivatives of 1- arylsulfonyl indoles and indazoles, having 5-HT6 receptor antagonist activity. WO Patent 2001032660, 2001.
125. Kelly, M.G.; Cole, D.C. Preparation of 1-alkylsulfonylheterocyclylbenzazolesand related compounds as 5- hydroxytryptamine-6 ligands. US Patent 2004192749, 2004.
126. Bernotas, R.C, Lenicek, S.E.Preparation of 1-heterocyclylalkyl-3- sulfonylindoles and indazoles as 5-HT6 ligands. WO Patent 2004009548, 2004.
127. Bernotas, R.C.; Yan, Y. Heterocyclyl-3-sulfonylazaindole orazaindazole derivatives as 5-HT6 receptor ligands, and their use for the treatment of central nervous system disorders. US Patent 2004167030, 2004.
128. Bernotas, R.C.; Lenicek, S.E.; Antane, S.A. 1-(Aminoalkyl)-3- sulfonylazaindoles as 5-hydroxytryptamine-6 ligands. WO Patent 2003101990, 2001.
129. Kelly, M.G.; Cole, D.C. 1-Ayrl- or 1-alkylsufonyl-heterocyclylbenzazolesas 5-hydroxytryptamine-6 ligands. WO Patent2002036562, 2006.
130. Elokdah, H.M.; Greenfield, A.A.; Liu, K.; McDevitt, R.E.; McFarlane, G.R.; Grosanu, C.; Lo, J.R.; Li, Y.; Robichaud, A.J.; Bernotas, R.C. Preparation of substituted-3-sulfonylindazole derivatives as 5-HT6 receptor modulators for treating CNS disorders. USPatent 2007037802, 2002.
131. Elokdah, H.M.; Greenfield, A.A.; Liu, K.; McFarlane, G.R.; Grosanu, C.; Lo, J.R, Robichaud, A.J. Preparation of azinyl-3- sulfonylindazolederivatives as 5-hydroxytryptamine-6 ligands. US Patent 2007054896, 2007.
132. Liu, K.G.; Robichaud, A.J.; Bernotas, R.C.; Yan, Y.F.; Lo, J.R.; Zhang, M.Y.; Hughes, Z. A.; Huselton, C.; Zhang, G.M.; Zhang, J.Y.; Kowal, D.M.; Smith, D.L.; Schechter, L.E.; Comery, T.A. 5- Piperazinyl-3-sulfonylindazoles as potent and selective 5- hydroxytryptamine-6 antagonists. J. Med. Chem., 2010, 53, 7639- 7646.
133. Haydar, S.N.; Andrae, P.M.; Yun, H.; Robichaud, A.J. 1- (Arylsulfonyl)-4-(piperazin-1-yl)-1H-benzimidazole compounds as 5-hydroxytryptamine-6 receptor ligands and their preparation and use in the treatment of diseases. U.S. Pat.Appl. US20100120779 A1, 2010.
134. Cole, D.C.; Bernotas, R.C. Preparation of arylsulfonyldihydrobenzimidazolones as serotonin 5-HT6 receptor ligands.U.S. Pat.Appl. US20050020575 A1, 2005.
135. Putman, D.G. Preparation of 2,5- and 2,6-substituted tetrahydroisoquinolines as 5-HT6 modulators, in particular selective 5-HT6 antagonists, for treating CNS disorders. PCT Int. Appl. WO2004078176 A1, 2004.
136. Zhao, S.H.; Berger, J.; Clark, R.D.; Sethofer, S.G.; Krauss, N.E.; Brothers, J.M.; Martin, R.S.; Misner, D.L.; Schwab, D.; Alexandrova, L. 3,4-Dihydro-2H-benzo[1,4]oxazine derivatives as 5-HT6 receptor antagonists. Bioorg. Med. Chem. Lett., 2007, 17, 3504- 3507.
137. Caldirola, P.; Johansson, G.; Sutin, L. Benzofuranyl derivatives as 5-HT6 receptor inhibitors, and therapeutic uses. PCT Int. Appl.WO2006134150 A1, 2006.
138. Dykes G. Preparation of piperazinylbenzofurans for the treatment of obesity, type II diabetes, and CNS disorders. WO Patent 2006062481, 2006.
139. Johansson, G.; Brandt, P.; Nilsson, B.M. Preparation of benzofuran derivatives that can be used in prophylaxis or treatment of 5-HT6 receptor-related disorders like obesity. WO Patent 2005058858, 2005.
140. Greenblatt, L.P. Preparation of piperidinylchromenylsulfonamides as 5-HT6 ligands. PCT Int. Appl. WO2005037830 A1, 2005.
141. Greenblatt, L.P.; Kelly, M.G. Preparation of 2- (aminoalkyl)chromans as 5-hydroxytryptamine-6 ligands for treatment of CNS disorders. WO Patent 2003029238, 2003.
142. Kelly, M.G.; Greenblatt, L.P.; Zhang, G.; Palmer, Y.L.; Lenicek, S.E. Preparation of 2-(aminoalkyl)chromans and benzofurans as 5- hydroxytryptamine-6 ligands for treatment of CNS disorders. WO Patent 2003029239, 2003.
143. Krauss, N.E.; Zhao, S.H. Preparation of chroman derivatives as 5- HT6 receptor ligands. PCT Int. Appl. WO2006066756 A1, 2006.
144. Chu. C.; Lister, A.; Nordvall, G.; Petersson, C.; Rotticci, D.; Sohn, D. Preparation of 8-sulfonylamino-3-amino-substituted chroman or tetrahydronaphthalene derivatives modulating the 5HT6 receptor for treating Alzheimer's disease, cognitive impairment associated with schizophrenia, obesity and/or Parkinson's disease. WO Patent 2006126939, 2006.
145. Nordvall, G.; Petersson, C.; Rakos, L.; Sohn, D. Novel 8-sulfonyl- 3-amino-substituted chroman or tetrahydronaphthalene derivatives modulating the 5-HT6 receptor and their preparation and pharmaceutical compositions. WO Patent 2006126938, 2006.
146. Berger, J.; Zhao, S.-H.Preparation of arylsulfonyl benzodioxanes for modulating 5-HT6 receptor, 5-HT2A receptor or both.PCT Int.Appl.WO2005105776 A1, 2005.
147. Boes, M.; Riemer, C.; Stadler, H. Preparation of pyrazolopyrimidines and pyrazolotriazines with 5-HT6 receptor affinity. Eur. Pat. Appl. EP941994 A1, 1999.
148. Ivachtchenko, A.V.; Dmitriev, D. E.; Golovina, E.S.; Kadieva, M.G.; Koryakova, A. G.; Kysil, V.M.; Mitkin, O.D.; Okun, I.M.; Tkachenko, S.E.; Vorobiev, A.A. (3-Phenylsulfonylcycloalkano[e and d]pyrazolo[1,5-a]pyrimidin-2-yl)amines: potent and selective antagonists of the serotonin 5-HT6 receptor. J. Med. Chem., 2010, 53, 5186-5196.
149. Ivachtchenko, A.V.; Golovina, E.S.; Kadieva, M.G.; Kysil, V.M.; Mitkin, O.D.; Tkachenko, S.E.; Okun, I.M. Synthesis and structureactivity relationship (SAR) of (5,7-disubstituted 3- phenylsulfonylpyrazolo[ 1,5-a]pyrimidin-2-yl)-methylamines as potent serotonin 5-HT6 receptor (5-HT6R) antagonists. J. Med. Chem., 2011, 54, 8161-8173.
150. Ivachtchenko, A.V.; Golovina, E.S.; Kadieva, M.G.; Koryakova, A.G.; Mitkin, O.D.; Tkachenko, S.E.; Kysil, V.M.; Okun, I. 2- Substituted 5,6-dimethyl-3-phenylsulfonyl-pyrazolo[1,5-a]pyrimidines: new series of highly potent and specific serotonin 5-HT6 receptor antagonists. Eur. J. Med. Chem., 2011, 46, 1189-1197.
151. Ivachtchenko, A.V.; Golovina, E.S.; Kadieva, M.G.; Kysil, V.M.;Mitkin, O.D.; Vorobiev, A.A.; Okun, I. Antagonists of 5-HT6 receptors. Substituted 3-(phenylsulfonyl)pyrazolo[1,5-a]pyrido[3,4- e]-pyrimidines and 3-(phenylsulfonyl)pyrazolo[1,5-a]pyrido[4,3- d]-pyrimidines-synthesis and "structure-activity" relationship. Bioorg. Med. Chem. Lett. 2012, 22, 4273-4280.
152. Cole, D. C. Preparation of N-sulfonylheterocyclo-pyrrolylalkylamine compounds as 5-hydroxytryptamine-6 ligands. PCT Int. Appl. WO2005012311 A1, 2005.
153. Bernotas, R.C.; Yan, Y. Heterocyclyl-3-sulfonylazaindole orazaindazole derivatives as 5-HT6 receptor ligands, and their use for the treatment of central nervous system disorders. WO patent 2004074286, 2004.
154. Tripathy, R.; McHugh, R.J.; Bacon, E.R.; Salvino, J. M.; Morton, G.C.; Aimone, L.D.; Huang, Z.L.; Mathiasen, J.R.; DiCamillo, A.; Huffman, M.J.; McKenna, B.A.; Kopec, K.; Lu, L. D.; Qian, J.; Angeles, T.S.; Connors, T.; Spais, C.; Holskin, B.; Duzic, E.; Schaffhauser, H.; Rosse, G.C. Discovery of 7-arylsulfonyl- 1,2,3,4,4a,9a-hexahydrobenzo[4,5]furo[2,3-c]pyridines: identification of a potent and selective 5-HT6 receptor antagonist showing activity in rat social recognition test. Bioorg. Med. Chem. Lett., 2012, 22, 1421-1426.
155. Nirogi, R.; Shinde, A.; Daulatabad, A.; Kambhampati, R.; Gudla, P.; Shaik, M.; Gampa, M.; Balasubramaniam, S.; Gangadasari, P.; Reballi, V.; Badange, R.; Bojja, K.; Subramanian, R.; Bhyrapuneni, G.; Muddana, N.; Jayarajan, P. Design, synthesis, and pharmacological evaluation of piperidin-4-yl amino aryl sulfonamides: novel, potent, selective, orally active, and brain penetrant 5-HT receptor antagonists. J. Med. Chem., 2012, 21, 9255-69.
156. Tenbrink, R.E.; Kortum, S.W. Preparation of arylsulfones as 5-HT6 receptor modulators. WO Patent 2003072558, 2003.
157. Lee, M.; Rangisetty, J.B.; Pullagurla, M.R.; Dukat, M.; Setola, V.; Roth, B.L.; Glennon, R. A. 1-(1-Naphthyl)piperazine as a novel template for 5-HT6 serotonin receptor ligands. Bioorg.Med. Chem. Lett; 2005, 15, 1707-1711.
158. Sikazwe, D.; Bondarev, M.L.; Dukat, M.; Rangisetty, J.B.; Roth Bryan, L.; Glennon, R.A. Binding of sulfonylcontaining arylalkylamines at human 5-HT6 serotonin receptors. J. Med. Chem., 2006, 49, 5217-5225.
159. Greenhouse, R.; Harris, R. N., III; Jaime-Figueroa, S.; Kress, J.M.; Repke, D.B.; Stabler, R. S. Preparation of tetralin and indane derivatives and use as selective 5-HT6 and 5-HT2A receptor antagonists for treatment of CNS disorders. PCT Int. Appl. WO2006066790 A1, 2006.
160. Jasti, V.; Ramakrishna, V.S.N.; Kambhampati, R.S.; Shirsath, V.S.; Vishwottam, N.K. Preparation of indeno[2,1-a]indenes and isoindol[2,1-a]indoles as modulators of 5HT receptors. WO Patent 2005066184, 2005.
161. Mesquida, N.; Lopez-Perez, S.; Dinares, I.; Frigola, J.; Merce, R.; Holenz, J.; Perez, R.; Burgueno, J.; Alcalde, E. Identification of novel indanylsulfonamide guanylhydrazones as potent 5-HT6 serotonin receptor antagonists. J. Med. Chem., 2009, 52, 6153-6157.
162. Becker, O.; Lobera, M.; Melendez, R. E.; Sharadendu, A.; Wu, L.; Yu, X. Y.; Dhanoa, D. S.; Cheruku, S. R.; Marantz, Y.; Noiman, S.; Fichman, M.; Senderowitz, H.; Shacham, S.; Saha, A.; Orbach, P. Preparation of piperazinylarylamines as 5-HT6 modulators. PCT Int. Appl. WO2006081332 A1, 2006.
163. Tenbrink, R.E. Preparation of oxazinocarbazoles as 5-HT6 serotonin receptor modulators. PCT Int. Appl. WO2001009142 A1, 2001.
164. Kelly, M.G.; Greenblatt, L.P.; Zhang, G.; Palmer, Y.L.; Lenicek, S. E. Preparation of 2-(aminoalkyl)chromans and benzofurans as 5- hydroxytryptamine-6 ligands for treatment of CNS disorders. PCT Int. Appl. WO2003029239 A1, 2003.
165. Harris, R.N., III; Kress, J. M.; Repke, D.B.; Stabler, R.S. Preparation of aryloxy quinolines as 5-HT6 receptor antagonists. U.S. Pat.Appl. US20070027161 A1, 2007.
166. Arnt, J.; Bang-Andersen, B.; Grayson, B.; Bymaster, F.P.; Cohen, M.P.; De Lapp, N. W.; Giethlen, B.; Kreilgaard, M.; McKinzie, D. L.; Neill, J. C.; Nelson, D. L.; Nielsen, S. M.; Poulsen, M. N.; Schaus, J. M.; Witten, L. M. Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats. Int. J. Neuropsychopharmacol., 2010, 13, 1021-1033.
167. Singer, J.M.; Wilson, M.W.; Johnson, P.D.; Graham, S.R.; Cooke, L.W.; Roof, R.L.; Boxer, P.A.; Gold, L.H.; Meltzer, L.T.; Janssen, A.; Roush, N.; Campbell, J.E.; Su, T.Z.; Hurst, S.I.; Stoner, C.L.; Schwarz, J.B. Synthesis and SAR of tolylamine 5-HT6 antagonists. Bioorg. Med. Chem. Lett; 2009, 19, 2409-2412.
168. Harris, R.N., III; Repke, D.B.; Stabler, R.S. Preparation of quinolinone and benzoxazinone derivatives as 5-HT6 modulators. PCT Int. Appl. WO2004080969 A1, 2004.
169. Maag, H.; Sui, M.; Zhao, S.-H.Preparation of substituted benzoxazinones as selective 5-HT6 antagonists for treating central nervous system diseases and gastrointestinal tract disorders.U.S. Pat.Appl. US20040092512 A1, 2004.
170. Harris, R.N., III; Kress, J.M.; Repke, D.B.; Stabler, R.S. Dibenzoxazepinone derivatives as 5-HT6 and 5-HT2A receptor antagonists, their preparation, pharmaceutical compositions, and use in therapy. PCT Int. Appl. WO2006061126 A2, 2006.
171. de la Fuente, T.; Martin-Fontecha, M.; Sallander, J.; Benhamu, B.; Campillo, M.; Medina, R.A.; Pellissier, L.P.; Claeysen, S.; Dumuis, A.; Pardo, L.; Lopez-Rodriguez, M.L. Benzimidazole derivatives as new serotonin 5-HT6 receptor antagonists. Molecular mechanisms of receptor inactivation. J. Med. Chem., 2010, 53, 1357- 1369.
172. Hostetler, G.; Dunn, D.; McKenna, B.A.; Kopec, K.; Chatterjee, S. Lactam and oxazolidinone derived potent 5-hydroxytryptamine 6 receptor antagonists. Bioorg. Med. Chem. Lett., 2014, 24, 2094- 2097.
173. Hostetler, G.; Dunn, D.; McKenna, B.A.; Kopec, K.; Chatterjee, S. In search of potent 5-HT6 receptor inverse agonists.Chem. Biol. Drug Res., 2014, 83, 666-669.
174. Wilkinson, D.; Windfeld, K.; Colding-Jorgensen, E. Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate alzheimer's disease (LADDER): a randomised, double- blind, placebo-controlled phase 2 trial. The Lancet Neurology, 2014, 13, 1092-1099.
175. http://clinicaltrials.gov/show/ NCT01955161. (accessed September 21, 2014).
176. Studies found in clinical trials for PF-05212377: http://clinicaltrials.gov/ct2/results?term=PF-05212377+&Search= Search. (accessed September 21, 2014).
177. Studies found in clinical trials for SB-742457: http://clinicaltrials.gov/ct2/results?term=SB- 742457+&Search=Search (accessed September, 21 2014).
178. Studies found in clinical trials for ABT-354: http://clinicaltrials.gov/ct2/results?term=abt-354&Search=Search. (accessed September 21, 2014).
179. Profit up on new compound; big plans for SUVN-502: Suven: http://www.moneycontrol.com/news/results-boardroom/profitupnew- compound-big-plans-for-suvn-502-suven_822589.html
180. Medicines in development alzheimer's disease 2013. http://www.phrma.org/sites/default/files/Alzheimer's%202013.pdf. (accessed September 21. 2014).
181. SYN120 for the treatment of Alzheimer's disease and other cognitive disorders. http://www.biotie.com/en/investors/releases/ release?NewsItemID=1478642&NewsItemYear=2011. (accessed September 21, 2014).
182. EPIX pharmaceuticals announces statistically significant results in cognitive function from Phase 1b clinical trial of novel 5HT6 drug candidate. April 18, 2007. http://www.drugs.com/clinical_ trials/epix-pharmaceuticals-announcesstatisticallysignificantresults- cognitive-function-phase-1b- 645.html. (accessed September 21, 2014).
183. EPIX Pharmaceuticals Announces Discontinuation of PRX-00023 Clinical Development Program. March 20, 2008. http://www.r euters.c o m /article/2008/03/20/idUS99490+20-Mar-2008+ BW20080320. (Accessed September 21, 2014).
184. Medivation and Pfizer Announce Results from Phase 3 Concert Trial of Dimebon in Alzheimer's Disease. January 16, 2012. http://www.pfizer.com/news/press-release/press-releasearchivedetail/ medivation and pfizer announce results from phase 3 concert trial of dimebon in Alzheimer's disease. (Accessed September 21, 2014).
185. Studies found in clinical trials for SAM-531: http://clinicaltrials.gov/ct2/results?term=sam-531&Search=Search. (Accessed September 21, 2014).
186. Studies found in clinical trials for SAM-315: http://clinicaltrials. gov/ct2/results?term=sam315&Search=Search (accessed September 21, 2014).
187. Lundbeck's non-amyloid Alzheimer's move could embolden others: http://epvantage.com/Universal/View.aspx?type=Story&id= 461691&isEPVantage=yes (Accessed August 21, 2014).